Concepedia

Author

Brian K. Link

University of IowaORCID

Also Known As

B K Link, B Link, B. K Link, B. K. Link, B. Link, B.K. Link, BK Link, Brian K. Link, Brian K Link, Brian K. Link

620

Publications

23.9K

Citations

71

H-Index

89

Concepts

All Affiliations

University of IowaMayo Clinic in FloridaMayo Clinic in ArizonaMayo ClinicUniversity of Iowa Hospitals and Clinics
BK

About

Brian K. Link is an author at University of Iowa specializing in medicine, immunology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

33

55

5.3K

2

Health Sciences

13

14

802

3

Public Health

4

4

365

4

Allergy

2

2

254

5

Biostatistics

1

1

217

Brian K. Link

×

182

Publications

22.1K

Citations

67

H-Index

YearCitations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link,

Journal of Clinical Oncology

1998

2.8K

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy, Chip Stewart, Andrew Dunford,

Nature Medicine

2018

1.9K

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq,

Blood

2017

1.6K

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Jens G. Lohr, Petar Stojanov, Michael S. Lawrence,

Proceedings of the National Academy of Sciences

2012

977

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Carla Casulo, Michelle Byrtek, Keith Dawson,

Journal of Clinical Oncology

2015

818

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro,

The Lancet

2018

707

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Thomas A. Davis, Antonio J Grillo-López, Christine A. White,

Journal of Clinical Oncology

2000

688

Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

Julie M. Vose, Brian K. Link, Michael L. Grossbard,

Journal of Clinical Oncology

2001

416

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais,

Journal of Clinical Oncology

2014

399

Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission Tomography

Malik E. Juweid, Gregory A. Wiseman, Julie M. Vose,

Journal of Clinical Oncology

2005

387

Page 1